Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 46-2956775 (State or ...

Company Participants Operator The company's actual results may differ materially from those discussed in today's -- during this webcast for a variety of reasons, including those described in forward-looking statements and Risk Factors sections of the company's Form 10-K for the year of 2022 which was filed, March 24, 2023 and its other filings with the SEC which are available on the Investor Relations section of Jaguar's website. Except as required by law, Jaguar undertakes no obligation to update or revise ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 46-2956775 (State or other jurisd ...

Jaguar Health Inc. (NASDAQ:JAGX) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Lisa Conte - President, Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Conference Call Participants Operator Before I turn the call over to management, IÂ'd like to remind you that management may make forwardlooking statements relating to the matters as contained growth prospects for the company. Uncertainties regarding market acceptance of p ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q2 2022 Earnings Conference Call August 22, 2022 8:30 AM ET Company Participants Lisa Conte - Founder, President, and Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Conference Call Participants Operator Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market ac ...

Jaguar Health, Inc. (NASDAQ: JAGX) Overview – June 2022 Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding plans by Jaguar Health, Inc. ("Jaguar" or the "Company") and Napo Therapeutics S.p.A. ("Napo Therapeutics", formerly known as "Napo EU") to develop and commercialize crofelemer in Europe (excluding Russia) for HIV-related diarrhea, short bowel syndrome a ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Lisa Conte - Founder, President and Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Peter Hodge - Senior Director of IR, Business Development and Special Events Conference Call Participants Operator Before I turn the call over to management, I'd like to remind you that the -- that management may make forward-looking statements relating to such mat ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2021 Earnings Conference Call March 14, 2022 8:30 AM ET Company Participants Lisa Conte - Founder, President and Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Peter Hodge - Senior Director of IR, Business Development & Special Events Operator Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for th ...

Jaguar Health, Inc. (NASDAQ: JAGX) Overview – December 2021 Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding plans by Jaguar Health, Inc. ("Jaguar" or the "Company") and Napo Therapeutics S.p.A. ("Napo Therapeutics", formerly known as "Napo EU") to develop and commercialize crofelemer in Europe (excluding Russia) for HIV-related diarrhea and short bowel syn ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2021 Earnings Conference Call November 15, 2021 8:30 AM ET Company Participants Carol Lizak – Chief Financial Officer Lisa Conte – President and Chief Executive Officer Ian Wendt – Chief Commercial Officer Conference Call Participants Operator Before I turn the call over to management, I would like to remind you that management may make forwardlooking statements relating to such matters as continued growth prospects for the Company, uncertainties regarding market accepta ...